Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes
Biomolecules & Therapeutics
;
: 288-295, 2017.
Article
Dans Anglais
| WPRIM
| ID: wpr-160701
ABSTRACT
The incidence of polypharmacy-which can result in drug-drug interactions-has increased in recent years. Drug-metabolizing enzymes and drug transporters are important polypharmacy modulators. In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro. HEK293 cells and primary human hepatocytes overexpressing the target genes were treated with bosentan and various concentrations of rifampin, which decreased the uptake activities of OATP transporters in a dose-dependent manner. In primary human hepatocytes, CYP2C9 and CYP3A4 gene expression and activities decreased upon treatment with 20 μM bosentan+200 μM rifampin. Rifampin also reduced gene expression of OATP1B1, OATP1B3, and OATP2B1 transporter, and inhibited bosentan influx in human hepatocytes at increasing concentrations. These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Rifampicine
/
Techniques in vitro
/
Expression des gènes
/
Incidence
/
Polypharmacie
/
Hépatocytes
/
Cytochrome P-450 enzyme system
/
Cytochromes
/
Transporteurs d'anions organiques
/
Cytochrome P-450 CYP3A
Type d'étude:
Etude d'incidence
/
Étude pronostique
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Biomolecules & Therapeutics
Année:
2017
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS